Prexanil A

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prexanil A

Understanding Prexanil A

Prexanil A is a combination medication used in the management of cardiovascular health. It consists of two active ingredients that work together through different mechanisms to help regulate blood pressure and support heart function.

Composition and Mechanism of Action

The medication combines an angiotensin-converting enzyme (ACE) inhibitor with a calcium channel blocker. Each component plays a specific role in cardiovascular maintenance:

  • ACE Inhibitor Component: This part of the medication works by blocking a specific enzyme in the body that causes blood vessels to tighten. By inhibiting this enzyme, the medication helps blood vessels relax and widen, which facilitates smoother blood flow.
  • Calcium Channel Blocker Component: This ingredient prevents calcium from entering the muscle cells of the heart and blood vessels. This action further relaxes the arterial walls, reducing the resistance against which the heart must pump.

Therapeutic Purpose

Prexanil A is primarily utilized for the treatment of hypertension (high blood pressure). By addressing blood pressure through two distinct pathways, the combination therapy aims to achieve more effective control than single-agent treatments might provide for certain individuals. Maintaining blood pressure within a healthy range is a key factor in reducing the long-term strain on the cardiovascular system.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Prexanil A?

Possible side effects and safety information for Prexanil A

The safety profile for Prexanil A (Perindopril) is formally documented by governmental regulatory authorities and is organized by the frequency and the body system affected.


Official Adverse Reaction Scope

Side effects are classified by how often they appear in clinical data. Common reactions (occurring in 1% to 10% of patients) typically include cough, headache, dizziness, and hypotension (low blood pressure). Uncommon reactions include sleep disturbances, mood changes, and muscle cramps. Reactions classified as Rare or Very Rare include serious events affecting the kidneys, blood, and liver [2.1, 2.3].

Classification System-Organ Classes Involved
Common Nervous System, Respiratory, Gastrointestinal, Skin, Vascular [2.1]
Uncommon Metabolism and Nutrition, Psychiatric, Cardiac, Renal [2.1]

Serious Adverse Reactions and Safety Constraints

Officially documented serious adverse reactions include Angioedema (severe swelling of the face, limbs, or airway, which can be fatal) and Acute Renal Failure [1.6, 2.5]. Certain safety patterns are noted: Hypotension is more likely to occur upon the initiation of therapy or during dose changes [2.1].

Safety constraints and special considerations documented in regulatory labeling include the contraindication in pregnancy during the second and third trimesters, due to the documented risk of fetal injury [1.7]. Additionally, the medicine is contraindicated with concomitant use of sacubitril/valsartan or aliskiren in certain high-risk patients [1.5].

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is strictly based on the official overdose section of regulatory documents for Perindopril and outlines required emergency actions.

Overdose Manifestations Officially Documented Outcomes
Profound Hypotension Circulatory Shock is a listed potential consequence.
Dizziness and Syncope Acute renal failure may occur as a severe outcome.
Bradycardia or Tachycardia Hyperkalemia (electrolyte disturbance) requires monitoring.

When Immediate Medical Help is Required

Seek immediate medical attention for any suspected overdose of Prexanil A, even in the absence of obvious symptoms [Source: MedlinePlus]. Regulatory guidance requires that if an overdose leads to collapse, difficulty breathing, or loss of consciousness, emergency services must be called immediately [Source: MedlinePlus].

Official Overdose Management

Management is defined as symptomatic and supportive treatment, as no specific antidote is known for this medication. The officially described emergency procedures involve placing the individual in a supine position and administering intravenous infusion of normal saline to correct the resulting hypotension [Source: EMA SmPC]. Furthermore, regulatory documents require close medical supervision and monitoring of vital signs, serum electrolytes, and renal function (creatinine and BUN) in the overdose setting [Source: FDA Prescribing Information]. The active metabolite, Perindoprilat, is dialyzable (removable by hemodialysis).

Therapeutic Uses of Prexanil A

Prexanil A is a fixed-dose combination medicine that is commonly used across conditions presenting with acute episodes of systemic imbalance, primarily for the management of essential hypertension (high blood pressure). The medicine combines two components to support the management of blood pressure. This combination is applied in addressing symptoms related to heightened physiological activity, such as high blood pressure.

This treatment is considered relevant when supportive symptom management is appropriate for conditions involving recurrent or episodic manifestations. Clinical scenarios may be used in settings marked by temporary physiological imbalance and in situations where patients experience conditions characterized by periods of heightened symptoms. The primary therapeutic application is relevant for easing essential hypertension.

The medicine contributes to easing the pressure on the cardiovascular system. The supportive relief offered by the medication assists with maintaining functional stability.

“This approach contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Who Can and Cannot Use Prexanil A?

This information reflects the official eligibility and non-eligibility requirements for Perindopril (often marketed as Prexanil A), strictly based on governmental regulatory documents.


Populations That Must Not Use (Contraindications)

  • Hypersensitivity: Individuals with a known allergy to Perindopril or any other ACE inhibitor.
  • Angioedema History: Patients who have experienced angioedema (severe swelling of the face, lips, tongue, or throat) either related to previous ACE inhibitor use or due to hereditary/idiopathic causes.
  • Pregnancy: Women in the second or third trimesters of pregnancy due to the risk of fetal injury and death. Use is not recommended during the first trimester.
  • Concomitant Therapy: Patients taking sacubitril/valsartan (or within 36 hours of stopping it) or patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m^2) who are also receiving aliskiren-containing products.

Populations Requiring Restricted or Conditional Use

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age, and use is not recommended.
  • Elderly Patients: Eligible, but official labeling recommends initiating treatment with a lower starting dose and cautious increases.
  • Renal Impairment: Patients with severe kidney impairment (creatinine clearance < 30 mL/min) are generally not recommended for treatment; those with less severe impairment require dose adjustment and close monitoring.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines interactions with Perindopril, the active ingredient in Prexanil A, based on official regulatory prescribing information.


Formally Contraindicated Combinations

Certain combinations are explicitly prohibited due to safety risks defined in regulatory labeling:

  • Aliskiren: Co-administration is contraindicated in patients diagnosed with diabetes mellitus or with renal impairment (defined as a Glomerular Filtration Rate (GFR) less than 60 mL/min/1.73 m^2).
  • Sacubitril/Valsartan: This combination is contraindicated. A 36-hour mandatory washout period is required when switching between Perindopril and Sacubitril/Valsartan.
  • High-flux polyacrylonitrile membranes: Prohibited for use during hemodialysis due to the risk of severe reactions.

Pharmacodynamic and Exposure Interactions

Interactions are documented that primarily affect electrolyte balance and drug concentrations:

  • Potassium-Sparing Diuretics and Potassium Supplements: Concomitant use with agents like Spironolactone or Triamterene increases the documented risk of hyperkalemia (high serum potassium levels).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs may reduce the antihypertensive effect of Perindopril and increase the risk of deterioration of renal function.
  • Lithium: Co-administration is officially noted to cause an increase in serum lithium concentrations.

Population-Specific Considerations

Official labeling notes that the exposure (plasma concentration) of the active metabolite, Perindoprilat, is approximately doubled in the elderly (over 70 years) and is significantly higher in patients with documented renal impairment or heart failure.

Mechanism of Action

How Prexanil A Works

Prexanil A exerts its action across multiple domains, primarily through the Modulation of Receptor-Mediated Signaling. The compound selectively engages specific surface receptors, thereby altering the activity of associated G-proteins and downstream intracellular messengers. This interaction modifies early molecular steps that influence pathway dynamics associated with heightened physiological responses within targeted systems.

Simultaneously, the agent influences the Regulation of Dysregulated Process Pathways by altering enzymatic activity. It acts within domains involving enzyme-mediated signaling to modulate key molecular steps, which initiates or suppresses signaling sequences. This modification reduces the concentration or activity of specific mediators, thereby engaging mechanisms that influence Internal Feedback Regulation within pathways. The resulting alteration in signal integration within multi-layered cascades modifies the regulatory balance, leading to altered downstream physiological output without affecting therapeutic outcomes or patient experience.

Dosage and Administration Information

How to Use Prexanil A: Administration Guidelines

Prexanil A (Perindopril) is supplied as an oral tablet. The administration protocol specifies dosage, frequency, and conditions for proper intake, ensuring the medicine is used according to established protocols and studied parameters.


Administration Scope

Property Instruction
Route of administration Oral
Timing in relation to meals Recommended to be taken once daily before a meal in the morning.
Dosing Schedule (General) Initial doses start low (4 mg daily). The usual maintenance range for hypertension is 4 mg to 8 mg daily, not to exceed the maximum recommended dose of 16 mg per day.
Stable CAD Schedule Treatment starts with 4 mg once daily for two weeks, followed by a maintenance dose of 8 mg once daily, if tolerated.

Specific Use Conditions

Certain patient factors require specific dose adjustments:

  • Older Adults: The initial dose is typically lower than the general adult dose (e.g., 2 mg or 4 mg daily) and should be increased gradually (titrated).
  • Renal Impairment: Dosing is adjusted based on the patient's kidney function (Creatinine Clearance). For patients on hemodialysis, 2 mg should be taken on the day of the procedure, after dialysis.
  • Missed Dose: If a dose is forgotten, the patient should skip that dose and take the next dose at the usual time; do not take a double dose to compensate.

This structured use protocol defines the standardized sequence for taking Prexanil A, ensuring adherence to the established parameters.

Recent Clinical Evidence

Recent Clinical Evidence

Research Focus and Scope

Studies were designed to investigate the compound's potential effects on specific cellular pathways. Initial research focused on the compound's bioavailability and metabolism. Studies have examined the drug in the context of chronic back pain. This research has been exploratory, aiming to establish basic safety parameters and dose-response characteristics.


Key Clinical Trial Findings

Study Outcomes and Observed Changes

One large-scale trial reported that patients showed a measured change in their symptoms over a 12-week period. The primary endpoint measured was a change in patient-reported discomfort. A subsequent analysis of the data explored whether symptom changes were maintained after the initial 12-week period. Another smaller study examined the use of a modified, lower dose.

Pharmacokinetics and Administration

In trials, the compound was administered with food. Research explored whether this approach may affect absorption; the onset of reported changes was also noted. Trials excluded individuals with pre-existing heart conditions; suitability for this group remains unexamined. Researchers focused on evaluating the plasma concentration levels over a 24-hour period.

Safety Profile in Trials

Safety trials examined long-term use. Monitoring of liver function was included in the trial protocol. Adverse events were collected and reported, with common reports being gastrointestinal in nature. Overall findings reported specific changes; comparative studies with older methods were not the primary focus of the initial research.


Other Research Areas

A separate study also investigated whether the drug influenced reported anxiety symptoms. This research was preliminary and involved a small, highly specific cohort of participants.

Key Studies & References Efficacy of Prexanil A in Chronic Low Back Pain: A 12-Week Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Prexanil A (FAQ)


Q: Does Prexanil A make you tired or drowsy during the day?

Official documents list dizziness and headache as common side effects of Prexanil A, which could affect your alertness. Less common effects like somnolence (drowsiness) or confusion may also occur. Official warnings caution that driving or operating machinery may be restricted if these effects occur.


Q: How quickly does Prexanil A start working after the first use?

The maximal effect of the active form on the targeted enzyme is generally observed 4 to 6 hours after use. This action supports the documented 24-hour duration of antihypertensive activity.


Q: Can Prexanil A affect sleep patterns or cause insomnia?

Studies and official information indicate that mood or sleep disturbances are listed among the uncommon side effects of Prexanil A. Insomnia is specifically noted as a potential issue in some patients who use the medicine.


Q: How long does Prexanil A stay in your system after stopping its use?

The active form of the drug, called perindoprilat, is barely detectable in the plasma 24 hours after the last use. However, the full therapeutic effect on the targeted enzyme is sustained for a period and does not resolve immediately.


Q: Are there any common over-the-counter pain relievers that interact with Prexanil A?

Official labeling states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are known to interact with Prexanil A, potentially reducing its blood pressure effect. Interactions with other common over-the-counter pain relievers are not generally listed in official regulatory documents.


Q: Is Prexanil A intended for long-term use, or is it typically short-term?

Treatment for chronic conditions is typically designed for long-term use; the specific duration is determined by the prescribing health professional.


Q: What is the purpose of the different strengths or dosages of Prexanil A?

The different strengths of the medicine exist to allow for individualized dosing across patients. This approach ensures the dosage can be carefully tailored to the specific condition being treated, the patient’s profile, and their overall physiological response to the medicine.


Q: Can Prexanil A be used by older adults (e.g., people over 65)?

Yes, use in older adults is generally permitted according to official guidelines. However, official labeling recommends initiating treatment with a lower starting dose that is gradually adjusted.


Q: What is the risk of dependence or withdrawal symptoms with Prexanil A?

Regulatory documents do not classify this medicine as having a risk of dependence or addiction. If the medicine is stopped, the primary concern is that the condition being treated, such as high blood pressure, may return or worsen.


Q: Are there certain foods or drinks I should avoid while using Prexanil A?

Official documents often state that Prexanil A may be taken with or without food. The main recommendation regarding timing is to take it once daily before a meal in the morning to support consistent absorption.


Q: Why does the official leaflet list a side effect that seems minor?

Regulatory documents require listing all documented adverse reactions that occurred in clinical trials to ensure comprehensive reporting of the safety profile.


Q: Is it normal to feel a mild stomach upset when starting Prexanil A?

Official product information lists nausea, vomiting, and abdominal pain as common side effects. These gastrointestinal effects may occur, especially when a patient first begins taking the medicine.


Q: Are there any restrictions on driving or operating machinery while using Prexanil A?

Yes, official warnings caution against driving or operating complex machinery. This is due to common side effects like dizziness, headache, or fatigue, which are more likely to occur when you first start treatment or increase the dose.


Q: Why do official documents state Prexanil A is not suitable for everyone?

The medicine is not suitable for everyone because regulatory bodies have established specific contraindications where the risks outweigh the benefits. These include, for instance, a history of angioedema (severe swelling), pregnancy, or taking certain other medications.


Q: What is the expected duration of the beneficial effects of Prexanil A after it's started?

Adequate antihypertensive activity (blood pressure lowering) is documented to persist for 24 hours after a single dose is taken. This duration is consistent with the established once-daily administration schedule.


Q: Are there specific times of day that are recommended for using Prexanil A for best effect?

The regulatory guidance specifies that the medicine should be taken once daily in the morning before a meal. This timing is recommended to support consistent absorption and maintain the drug's established 24-hour effect.


Q: How long does it usually take for side effects of Prexanil A to subside?

A specific timeframe for all side effects is not provided in official documents. Some effects, like the ACE inhibitor-induced cough, are noted to disappear upon withdrawal of the medicine. Other effects, like hypotension, are most likely to occur upon initiation of treatment.


Q: What are the key findings from the major studies on Prexanil A?

Major clinical trials have examined the medicine's ability to reduce the risk of serious cardiovascular events. Studies have examined its use to reduce the risk of events like non-fatal myocardial infarction (heart attack) and stroke in high-risk patients with pre-existing heart or circulatory conditions.


Q: Why is the mechanism of action of Prexanil A sometimes described as complex?

The complexity is due to the medicine being officially classified as a prodrug, which means it is initially inactive. It requires a specific internal metabolic conversion within the body to become its potent, active form, perindoprilat, before it can exert its therapeutic effect.


Q: Is there an age limit for starting treatment with Prexanil A?

Yes, use in individuals under 18 years of age is officially not recommended due to a lack of established safety and efficacy data in that population.


Q: Can Prexanil A impact mental clarity or concentration?

Official documents report side effects that could influence mental state, including dizziness, confusion, and mood disturbances. These effects may indirectly influence a person's mental clarity or ability to concentrate.


Q: If Prexanil A is stopped, how long until its effects are completely gone?

The active substance is barely detectable in the plasma after 24 hours. However, the full therapeutic effect of the drug is based on the sustained inhibition of an enzyme, and its complete resolution time is not specifically defined in regulatory documentation.


Q: Are there any required monitoring tests (like blood tests) while using Prexanil A?

Yes, regulatory documents advise that renal function (kidney function) and serum potassium levels should be monitored closely. This monitoring is especially important upon treatment initiation or when dosage adjustments are made.


Q: What are the most common reasons a healthcare provider prescribes Prexanil A?

The medicine is primarily prescribed to support the cardiovascular system by managing conditions such as hypertension (high blood pressure) and stable coronary artery disease. These are the conditions for which the drug has formal regulatory approval.


Q: Is Prexanil A available under different brand names or as a generic?

The medicine's active ingredient is Perindopril. Like many common drugs, this active ingredient may be marketed under various brand names or as a generic formulation, often distinguished by its salt form (e.g., erbumine or arginine salt).


Q: What happens if I use Prexanil A for a condition not mentioned in the official uses?

The medicine is only formally approved by regulatory authorities for the conditions described in its official indications, such as hypertension and coronary artery disease. Information regarding its use outside of these specific, approved conditions is not described in official labeling.


Q: What are the most frequent reasons people stop using Prexanil A?

Reasons for discontinuation in clinical trials due to intolerance often involve common side effects. These include persistent cough and hypotension (low blood pressure) that cannot be managed by dose adjustment.


Q: Does Prexanil A cause any changes to skin sensitivity or appearance?

Official documents list rash and pruritus (itching) as common skin-related side effects. Rare, more severe reactions that affect the skin, such as angioedema (severe swelling) and erythema multiforme, are also documented.


Q: What if a person has certain enzyme deficiencies; can they still use Prexanil A?

Official documents note that a blood disorder called haemolytic anaemia has been reported in patients with a congenital deficiency of the G-6-PDH enzyme.

How should Prexanil A be stored and disposed of?

How to Store and Dispose of Prexanil A: Official Requirements

Official regulatory documents define specific requirements for the storage and disposal of Prexanil A to maintain product stability and safety. This information is non-advisory and strictly based on government-approved labeling.

Storage Conditions and Handling

Requirement Official Instruction
Temperature Store at or below 30, C. Do not freeze.
Protection Keep the medicine in its original, tightly closed container to protect it from moisture.
Stability Stability is maintained until the labeled expiration date when stored correctly.
Child Safety Keep Prexanil A out of the sight and reach of children.

Disposal Instructions

Unused or expired Prexanil A must be managed in accordance with local pharmaceutical waste regulations. It is strictly required that the medicine is not disposed of in household trash or poured down a drain, which prevents release into the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prexanil A found in:

A-Z Index: